...We Welcome You to the Zenith Epigenetics Hub withIn The AGORACOM COMMUNITY!

Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials

Free
Message: otc zen

If we are going to be sitting here in the same position 5-6 years from now I'd rather see them sell for less $$$ now.  If there was an offer for $7 US per share for the company today, I'd vote yes.

 

Share
New Message
Please login to post a reply